Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP ARNOUK, Rene
BELLUCCI, Carlos Henrique Suzuki
STULL, Roberto Benatuil
MALAVE, Cesar Augusto
GOMES, Cristiano Mendes FMUSP-HC 2012
dc.identifier.citation SCIENTIFIC WORLD JOURNAL, article ID 463574, 6p, 2012
dc.identifier.issn 1537-744X
dc.description.abstract Purpose. To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods. Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Q(max)), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups. Results. Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Q(max) and PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups. Conclusions. Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.
dc.language.iso eng
dc.relation.ispartof Scientific World Journal
dc.rights openAccess
dc.subject.other toxin type-a; urinary-tract symptoms; long-term; injection; finasteride; dyssynergia; retention; therapy; relief; men
dc.title Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses
dc.type article
dc.rights.holder Copyright HINDAWI PUBLISHING CORPORATION LIM/55
dc.identifier.doi 10.1100/2012/463574
dc.identifier.pmid 22997495
dc.type.category original article
dc.type.version publishedVersion GOMES, Cristiano Mendes:HC:IOT · ARNOUK, Rene:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela
· BELLUCCI, Carlos Henrique Suzuki:Uroclin Joinville, BR-89201700 Joinville, SC, Brazil
· STULL, Roberto Benatuil:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela
· BESSA JUNIOR, Jose de:Univ Estadual Feira de Santana, Div Urol, BR-44031460 Feira De Santana, BA, Brazil
· MALAVE, Cesar Augusto:Dr Carlos Arvelo Mil Hosp, Dept Urol, Caracas 1060, Miranda, Venezuela WOS:000308605900001 2-s2.0-84867806302 NEW YORK USA
hcfmusp.relation.reference · Apostolidis A, 2005, J UROLOGY, V174, P977, DOI 10.1097/01.ju.0000169481.42259.54
· Barry MJ, 2001, BRIT MED J, V323, P1042
· Brisinda G, 2009, UROLOGY, V73, P90, DOI 10.1016/j.urology.2008.08.475
· Chuang YC, 2006, J UROLOGY, V175, P1158, DOI 10.1016/S0022-5347(05)00318-6
· Chuang YC, 2006, BJU INT, V98, P1033, DOI 10.1111/j.1464-410X.2006.06479.x
· Chuang YC, 2005, UROLOGY, V66, P775, DOI 10.1016/j.urology.2005.04.029
· Chuang Yao-Chi, 2006, BMC Urol, V6, P12, DOI 10.1186/1471-2490-6-12
· Clifford GM, 2000, EUR UROL, V38, P2, DOI 10.1159/000020246
· de Miguel F, 2006, Actas Urol Esp, V30, P310
· de la Rosette JJMCH, 2001, EUR UROL, V40, P256, DOI 10.1159/000049784
· Doggweiler R, 1998, PROSTATE, V37, P44, DOI 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8
· DYKSTRA DD, 1988, J UROLOGY, V139, P919
· Kuo HC, 2005, UROLOGY, V65, P670, DOI 10.1016/j.urology.2004.10.077
· Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801
· Lim SK, 2008, EUR UROL, V53, P620, DOI 10.1016/j.eururo.2007.10.001
· LUYAO GL, 1994, UROLOGY, V44, P692, DOI 10.1016/S0090-4295(94)80208-4
· MACKENZIE I, 1982, NEUROSCIENCE, V7, P997, DOI 10.1016/0306-4522(82)90056-2
· Maria G, 2003, UROLOGY, V62, P259, DOI 10.1016/S0090-4295(03)00477-1
· McConnell J. D., 1994, TREATING TOBACCO USE, P1
· McConnell JD, 1998, NEW ENGL J MED, V338, P557, DOI 10.1056/NEJM199802263380901
· Narayan P, 2001, UROLOGY, V57, P466, DOI 10.1016/S0090-4295(00)01042-6
· Nasu K, 1996, BRIT J PHARMACOL, V119, P797
· Park DS, 2006, YONSEI MED J, V47, P706
· Schurch B, 2000, J UROLOGY, V164, P692, DOI 10.1016/S0022-5347(05)67283-7
· Schurch B, 2005, J UROLOGY, V174, P196, DOI 10.1097/01.ju.0000462035.73977.1c
· Silva J, 2008, EUR UROL, V53, P153, DOI 10.1016/j.eururo.2007.08.050
dc.description.index MEDLINE
hcfmusp.citation.scopus 11
hcfmusp.citation.wos 10 Brasil Venezuela

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account